Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 8/20 | 0.41 |
| ▸ | OGA | O60502 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26923489 | 1.00 | GPR55 (0.43) | GPR55PDE2AOGAKIF11CTNNB1 | |
| SCHEMBL20559520 | 1.00 | GPR55 (0.43) | GPR55PDE2AOGAKIF11CTNNB1 | |
| Hydrochloric Acid SCHEMBL27126749 | 0.98 | GPR55 (0.42) | GPR55PDE2AOGAKIF11CTNNB1 | |
| Hydrochloric Acid SCHEMBL31461346 | 0.98 | GPR55 (0.42) | GPR55PDE2AOGAKIF11CTNNB1 | |
| Hydrochloric Acid SCHEMBL16989251 | 0.98 | GPR55 (0.42) | GPR55PDE2AOGAKIF11CTNNB1 | |
| Hydrochloric Acid SCHEMBL30239946 | 0.98 | GPR55 (0.42) | GPR55PDE2AOGAKIF11CTNNB1 | |
| SCHEMBL879006 | 0.85 | GPR55 (0.45) | GPR55PDE2AOGAKIF11CTNNB1 | |
| Hydrochloric Acid SCHEMBL26924000 | 0.84 | PDE2A (0.40) | GPR55PDE2AOGAKIF11CTNNB1 | |
| Hydrochloric Acid SCHEMBL26923999 | 0.84 | PDE2A (0.40) | GPR55PDE2AOGAKIF11CTNNB1 | |
| SCHEMBL12263549 | 0.82 | PDE2A (0.43) | GPR55PDE2AOGAKIF11CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119677730-A | Compounds, compositions, and methods of use thereof | 希安纳医疗公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-4309653-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Exithera Pharmaceuticals Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-115461327-A | Spiro urea derivatives | 爱杜西亚药品有限公司 | 2022-12-09 | — | — | CN | disclosed |
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-08-23 | — | — | US | disclosed |
| US-11198673-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-10259785-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3404021-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2018-11-21 | — | — | EP | disclosed |
| US-9994521-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170037003-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2017-02-09 | — | — | US | disclosed |
| US-9499532-B2 | Therapeutic compounds and compositions | eXIthera Pharmaceuticals Inc. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150225389-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | eXIthera Pharmaceuticals Inc. (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225389-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | eXIthera Pharmaceuticals Inc. (US) | 2015-08-13 | — | — | US | disclosed |
| WO-2015120062-A2 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | eXIthera Pharmaceuticals Inc. (US) | 2015-08-13 | — | — | WO | disclosed |
| EP-2155751-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2010-02-24 | — | — | EP | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037003-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | GPR55 2798/4885PDE2A 624/4885OGA 2405/4885 |
| US-20090099195-A1 | Therapeutic Compounds 570 | OPRL1, OPRK1, OPRM1 | GPR55 424/4885PDE2A 334/4885OGA 4733/4885 |
| US-11198673-B2 | Therapeutic compounds and compositions | KLK5, KLKB1, KLK2 | GPR55 2798/4885PDE2A 624/4885OGA 2405/4885 |
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | CACNA1I, CACNA1G, CACNA1E | GPR55 653/4885PDE2A 2308/4885OGA 4806/4885 |
| US-10259785-B2 | Therapeutic compounds and compositions | KLK5, KLKB1, KLK2 | GPR55 2798/4885PDE2A 624/4885OGA 2405/4885 |
| US-20150225389-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLKB1, KLK2 | GPR55 2798/4885PDE2A 624/4885OGA 2405/4885 |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1E | GPR55 587/4885PDE2A 2796/4885OGA 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.